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Abstract
The poor response to the combined antiviral therapy of pegylated alfa-interferon and ribavarin for hepatitis C virus (HCV)
infection may be linked to mutations in the viral envelope gene E1E2 (env), which can result in escape from the immune
response and higher efficacy of viral entry. Mutations that result in failure of therapy most likely require compensatory
mutations to achieve sufficient change in envelope structure and function. Compensatory mutations were investigated by
determining positions in the E1E2 gene where amino acids (aa) covaried across groups of individuals. We assessed networks
of covarying positions in E1E2 sequences that differentiated sustained virological response (SVR) from non-response (NR) in
43 genotype 1a (17 SVR), and 49 genotype 1b (25 SVR) chronically HCV-infected individuals. Binary integer programming
over covariance networks was used to extract aa combinations that differed between response groups. Genotype 1a E1E2
sequences exhibited higher degrees of covariance and clustered into 3 main groups while 1b sequences exhibited no
clustering. Between 5 and 9 aa pairs were required to separate SVR from NR in each genotype. aa in hypervariable region 1
were 6 times more likely than chance to occur in the optimal networks. The pair 531–626 (EI) appeared frequently in the
optimal networks and was present in 6 of 9 NR in one of the 1a clusters. The most frequent pairs representing SVR were
431–481 (EE), 500–522 (QA) in 1a, and 407–434 (AQ) in 1b. Optimal networks based on covarying aa pairs in HCV envelope
can indicate features that are associated with failure or success to antiviral therapy.
Citation: Murray JM, Moenne-Loccoz R, Velay A, Habersetzer F, Doffoe¨l M, et al. (2013) Genotype 1 Hepatitis C Virus Envelope Features That Determine Antiviral
Response Assessed through Optimal Covariance Networks. PLoS ONE 8(6): e67254. doi:10.1371/journal.pone.0067254
Editor: Jason D. Barbour, University of Hawaii Manoa, United States of America
Received January 19, 2013; Accepted May 14, 2013; Published June 20, 2013
Copyright:  2013 Murray et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the European Union (ERC-2008-AdG-233130-HEPCENT, INTERREG-IV-Rhin Supe´rieur-FEDER-Hepato-Regio-Net 2009), the
chair of excellence program of the Agence Nationale de la Recherche France (ANR-05-CEXC-008), ANRS (2011/132, 2011/154, 2012/239&319, 2012/318), DGOS
Inserm A12027MS, the University of Strasbourg and Laboratoire d’excellence LabEx HEPSYS (ANR-10-LAB-28). E. Schvoerer thanks the Fondation Transplantation
(France), Region Alsace (France), Region Lorraine (France), Abbott Molecular (France) and Roche (France) for unrestricted financial support. The funders had no
role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: Abbott Molecular and Roche provided funding towards this study. There are no patents, products in development or marketed products
to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.
* E-mail: J.Murray@unsw.edu.au
Introduction
Poor response rates for hepatitis C virus (HCV) infection are
obtained by current combination antiviral therapy with pegylated
alfa-interferon (IFN-a) and ribavarin (RBV) where only 45% of
individuals with genotype 1 experience a sustained virological
response (SVR, undetectable HCV RNA 6 months after the end of
therapy). Success in therapy is determined by a number of host
and viral factors including the patient’s adherence to therapy,
IL28B genotype, viral load and genotype [1–5]. The viral
sequence can certainly affect the success rate of therapy since
genotype 1 has poorer rates of SVR and even within that
genotype, patients with 1a virus are less successful than patients
with 1b virus [6]. For treatment that includes interferon, a drug
that stimulates antiviral cytokines, failure of therapy for immuno-
logical reasons is even more likely determined by the viral
sequence. New anti-HCV drugs such as the protease inhibitors
telaprevir and boceprevir are now available for HCV genotype 1
treatment, but they are administered in tritherapy with IFN-alfa
and RBV, which remains the backbone of anti-HCV treatment.
Although coadministration of protease inhibitors improves SVR
rates, treatment failure due to viral resistance and adverse events
remain important challenges [7,8].
It has been demonstrated that evasion from the immune
response is linked to mutations in the envelope gene. The E1E2
region of the HCV genome (env) codes for the envelope E1 and E2
glycoproteins on the surface of virions, that are crucial in binding
to target cells and are also themselves targets for the immune
response. Mutations in this region lead to escape from neutralizing
antibody and T cell responses [9], but can also affect infectivity
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[10–12]. Viral entry into hepatocytes is mediated by a number of
host cell factors that link with the E1E2 glycoproteins. The
hypervariable region 1 (HVR1) of E2 interacts with scavenger
receptor BI (SR-BI) and highly sulfated heparin sulphate (HS)
[13]. CD81 binds to a number of domains within E2 [14].
Mutations within this region can therefore be expected to have an
impact on success of antiviral therapy [15].
Investigation of the impact of mutations in envelope can be
complicated due to the high variability of this gene and the
resulting difficulty in determining which mutations produce a
functionally different phenotype. Our group has recently assessed
the influence of single mutations from HCV env sequences on
antiviral response through a combined bioinformatics and in vitro
analysis. By constructing HCV pseudoparticles that expressed an
alanine (A) at position 431, or a valine (V) at position 642, we were
able to verify these 1a mutations, identified in an initial
bioinformatics analysis, significantly decreased antibody neutral-
ization, while the 431A mutation also increased entry of virus into
Huh7.5 cells that over-expressed CD81 and SR-B1 [16]. However
bioinformatics analyses by themselves have less power to
determine single aa predictors of response, given any cohort
usually includes considerably fewer patient sequences than the 555
aa in the envelope sequences.
Networks of positions in E1E2 where the aa covary across
groups of patients likely indicate a connection between the aa that
are required for function. The set of all covarying aa pairs offers a
more robust basis upon which to extract information within E1E2
that i) is relevant to function, ii) that may be used as a means of
predicting response, and iii) that can implicate regions instrumen-
tal in HCV-related mechanisms of treatment failure. This method
of determining relatedness in genes has been used previously [17–
20], as well as in the context of HCV [21]. Networks that use the
covarying pairs as building blocks can generate sets that contain
the many compensatory mutations required for a different
functional response.
However sets of covarying pairs can be large and can also
provide many choices for separation between response groups.
Hence we investigated methods that included as few pairs as
possible in the set associated with response, reasoning that such
sets would contain the most important individual features, and also
point to biologically relevant positions. We therefore determined
minimal sets of aa pairs that could successfully separate good
responders (SVR) from poor responders (NR). These minimal
separation methods were investigated on pretreatment E1E2
sequences obtained from 92 individuals infected with HCV
genotypes 1a or 1b, and receiving therapy of IFN-a and RBV
[16].
Methods
Patients
Pre-treatment serum samples were collected from 92 patients
infected by HCV genotype 1 (1a, n = 43; 1b, n= 49) followed at
the hospitals: Centre Hospitalier-Universitaire (CHU) Strasbourg
n= 44; CHU Tours n= 7; CHU Clermont-Ferrand n= 3; CHU
Bobigny n= 16; CHU Villejuif n = 6; CHU Toulouse n= 5;
Hoˆpital Pitie´-Salpeˆtrie`re, Paris n= 5; CHU Bordeaux n= 4; CHU
Brest n= 2. Approval of the study was obtained by the ‘‘Comite´ de
Protection des Personnes – CPP d’Alsace’’ (19/11/2008, DC-
2008-829), in accordance with the ethical guidelines of Helsinki.
The study was realized on a sample collection performed in the
context of classical viro-clinical follow-up by physicians who take
care of their patients suffering from chronic hepatitis C. The
physicians informed their patients that remaining blood sample
volumes could be used for research on HCV treatment. They have
then checked the verbal non-opposition from their patients who
were given the information on the viro-clinical study (file available
on request). Indeed, verbal non-opposition is convenient in this
context (checked in 2008 with Clinical Research Authorities,
University Hospital, Strasbourg). The local ethical authorities
‘‘Comite´ de Protection des Personnes – EST IV’’, approved this
sample collection in 2010 (file available on request).
Alignment
Sequences were aligned with the reference strains H77 (1a) and
J4 (1b) using a progressive multiple alignment method (multialign,
Matlab 2010b). Pairwise distances were calculated with the Jukes-
Cantor method, with the phylogenetic tree generated using the
Unweighted Pair Group Method Average (seqlinkage).
Calculation of covariance values S
An S covariance value was determined for each aa pair position
based on the method of Aurora et al. [21]. These calculations were
performed separately for each genotype, as well as for each of the
SVR and NR groups within these genotypes. We then extracted
the covarying pairs above a background cut-off value Sw0:5 [21].
Networks
We calculated sets of covarying pairs Pgeno,group, for each
genotype (a or b), and where the calculations were performed over
the group of all individuals within that genotype or separately for
NR or SVR (All, NR, SVR). These sets determined initial
networks where the aa formed the nodes, and edges connected aa
that appeared in the set of covarying pairs.
Our aim was to calculate minimal networks based on each of
these sets where we extract covarying pairs and particular aa
combinations for that pair where a feature is present in one
response group but not the other. For example aa at positions 373
and 438 might be covarying with 8 NR patients exhibiting a V at
position 373 and a D at 438 while no SVR patients exhibit this
feature of the VD combination. We term such pairs and aa
combinations as separating pairs. Calculations of minimal networks
were relevant to all possible separating pairs and so our first step
was to construct the network of these. The networks for each of the
analyses were constructed as outlined in the following example,
which demonstrates the process of selecting aa combinations
exhibited by one response group and not the other, in this case NR
and not by SVR, from the set of covarying pairs in the genotype 1a
SVR individuals Pa,SVR.
Example. From the set of covarying pairs determined on the
1a SVR sequences Pa,SVR, we extract aa combinations over these
pairs that are exhibited by sequences of the NR individuals but not
by the SVR individuals in genotype 1a. The set Pa,SVR consists of
681 pairs listed by their positions within E1E2: [(7,28), (7,46),
(7,139), …,(527,537), (527,548), (534,550)] involving 85 different
positions [7,25,26,…,537,548,555]. Of these 681 pairs only 561
exhibit separating pairs (at least one aa combination appearing in
NR sequences and not in SVR sequences). For instance at the
positions (7,139) there are 5 NR individuals expressing the
combination SA (a Serine at position 7 and an Alanine at position
139), while no SVR sequences exhibit this combination for this
pair of positions. The combination SA at position (7,139) is
therefore a separating pair. This combination was the only one
unique to NR for this covarying pair while other covarying pairs
exhibited between 0 and 16 separating pairs since there can be
more than one aa combination at a given pair of positions that are
exhibited by NR but not by SVR individuals. Over all covarying
pairs in Pa,SVR there were a total of 1,631 separating pairs.
HCV Features That Determine Antiviral Response
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The nodes of the network for this example are provided by the
subset of positions where a separating aa pair is incident. For this
example all 85 positions have at least one separating pair incident
to them and therefore form the nodes of the network.
Separation between the response groups can be determined
based on single separating aa pairs, or the entire collection of
separating pairs for the given positions. Accordingly the edges in
the network can be formed by single connections between aa pairs
where any separating pair exists if we allow multiple features in the
separation for each position, or with edges for each of the
separating aa pairs if we only allow a single separating aa pair to
be specified at each position. For example there are two separating
aa pairs for (7,207), TG and SG. If we allow multiple features at
each position in the separation then we include a single edge
between nodes 7 and 207 representing the 3 individuals with a TG
or SG at these positions. On the other hand if we only allow a
single feature to be selected at each position then we include an
edge representing the single individual with TG, and another edge
representing the 2 individuals with SG. Calculation of a minimal
network in the latter case includes constraints that only allow the
choice of a single edge between nodes.
Binary integer programming formulation of the problem
of choosing optimal pairs from networks
Constructing the network where there are edges between nodes
for each separating pair produces the coefficient matrix A^, while
representing all separating aa pairs between two nodes by a single
edge produces the coefficient matrix dAM . These networks and
corresponding coefficient matrices were produced for each of the
12 individual analyses.
These 0–1 coefficient matrices contain a row for each individual
(in NR for networks describing Poor Response and in SVR for
networks describing Good Response), and a column or columns
for the separating pairs at each covarying pair. This procedure is
described as follows, for construction of coefficient matrices for
Poor Response.
Suppose there are K patients in NR and L in SVR. We are also
given a set of aa pairs I with indices (i,j) where these represent the
pair positions in the viral sequence of the aa pair and where i is the
smallest index. For each index in I we determine the number of
different amino acid combinations for positions i and j that appear
in NR but not in SVR, Nij . Let us denote this ordered set of pairs
at these positions for patients in NR that do not appear in SVR as
separating pairs at (i,j). We then calculate the patient-pair matrix
A(i,j) with dimensions K|Nij where the k
th row and nth column is
1 if the kth patient in NR has the nth separating pair and 0
otherwise.
For example suppose there are 5 patients in NR and 6 in SVR
and at positions 1 and 2 in the amino acid sequence the patients
exhibit the aa pairs shown in Table 1. Then the aa pairs that
appear in NR but not in SVR are VS and AT. We let VS
represent the first of these and AT the second. The patient-pair
matrix is then given by
A(1,2)~
1 0
0 0
1 0
0 1
0 0
0
BBBBB@
1
CCCCCA
Patients 1 and 3 exhibited the first of these pairs so in the first
and third row there is a 1 in the 1st column. Patient 4 exhibited the
second of these pairs so in the 4th row there is a 1 in the second
column. All other entries are zero.
If we do not need to differentiate the different separating pairs
we can collapse each of these matrices into a single column by
using instead the matrix AM (i,j) that consists of the sum of the
above matrix over each row. This will also be a 0-1 matrix.
AM (1,2)~
1
0
1
1
0
0
BBBBB@
1
CCCCCA
For all pairs in the set I we construct the concatenated matrix of
these individual separating matrices
A^~½A
i1,j1ð ÞA i2,j2ð Þ . . .A ig,jgð Þ
Similarly we obtain the concatenated matrix dAM .
We wish to determine a set of aa positional pairs S5I that
exhibit the property such that for each patient in NR there is a
separating aa pair for this patient at some position (i,j)[S. This
constraint can be written as
A^x§e
where e is the vector of 1’s and x is a 0–1 column vector with the
same number of components as columns in the matrix A^ , if only a
single feature is to be chosen in each aa pair. We will need to apply
an additional constraint to ensure that only one of the columns
from the individual A(i,j) matrices corresponds to a 1 in the vector
x so that a single feature is chosen for each possible pair. If several
features can be chosen to separate the sets in each pair, then this
set of constraints is written as
Table 1. Example of separating pairs. aa pairs at positions 1
and 2.
Response Patient
aa at
posn 1
aa at
posn 2
NR 1 V S
2 A Y
3 V S
4 A T
5 A S
SVR 6 A S
7 V Y
8 V Y
9 A Y
10 A S
11 A Y
doi:10.1371/journal.pone.0067254.t001
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dAMxM§e
Some of the individual matrices A(i,j) will be empty as no feature
will separate the two sets at that pair. Therefore the columns of the
concatenated matrix A^ need not correspond in a one-to-one
fashion with the ordered set of pairs (i,j)f g5I .
Given a weight vector w for the inclusion of each separating pair
we obtain the binary programming problem described below.
Binary integer programs are a standard operation research
method of optimally choosing items from a set while satisfying
constraints [22].
minimize wTx
subject to A^x§e
Bxƒem
x binary
ð1Þ
The matrix B has rows corresponding to the number of A(i,j)
matrices that have more than one column. The elements of the kth
row of B are zero except where the columns correspond to the kth
matrix A(i,j) with multiple columns where it has values 1. This
constraint ensures only one of these columns can be chosen.
If multiple features can be chosen then the problem becomes
minimize wM
TxM
subject todAMxM§e
xM binary
ð2Þ
Different weight vectors
If wk = 1, for all k then minimization determines sets that use the
fewest number of pairs. Calculations of networks that maximized a
measure of total covariance, while keeping numbers of pairs small,
were performed through minimization with the weights
wk~S{Sk
where S is the integer ceiling of the maximum of all covariance
values S. This choice ensures the weights are nonnegative, the
minimization will preferentially include pairs with high S, and will
penalize the addition of pairs in general.
All calculations were performed with Matlab version R2010b
(The MathWorks Inc., USA). The binary integer programming
problems were solved using the bintprog routine.
Results
We investigated the response to antiviral therapy with IFN-a
and RBV, median duration of 9.9 months (range 6.4 to
13.4 months), in 92 HCV chronically infected individuals, 43 of
whom were infected with genotype 1a and 49 with genotype 1b.
Within genotype 1a, 17 individuals (40%) achieved SVR while
there were 25 SVR individuals (51%) in genotype 1b. The E1E2
sequences comprising approximately 555 amino acids, enabled
separation of genotypes phylogenetically as displayed in Figure 1.
SVR individuals were scattered through the phylogenetic tree for
each of the genotypes.
For each of the genotypes we calculated covarying aa pairs over
sequences in each group (Methods). Calculations over all
individuals in genotype 1a resulted in 1,095 pairs and 516 pairs
in genotype 1b, considerably smaller than the total number of
possible pairs (5556554/2= 153,735). The individual positions in
E1E2 contained in these covarying positions were largely
consistent with those found previously in an analysis over the
whole HCV genome. Positions within our covarying pair
calculations exhibited a 79% overlap with those in E1E2
determined by Aurora et al. [21], while 83% of the Aurora
positions also appeared in our calculations. Comparison of
covarying pairs however showed a substantially smaller overlap:
21% of our pairs were in the Aurora calculations while 28% of
their pairs appeared in our calculations.
Conserved and covarying regions for each genotype
Higher covariance between positions suggests that these
positions are functionally or structurally important for HCV.
These positions are therefore more relevant in that sense than
positions that are highly variable, but less relevant than conserved
positions. We mapped regions that were conserved, covarying and
variable in E1E2 over both genotypes and depicted them in
Figure 2. We note that the regions that are conserved separately in
genotypes (dark blue) appear in different regions of E1E2,
although two positions 275 (L in 1a, M in 1b) and 362 (F in 1a,
Y in 1b) were conserved differently in each genotype. Although the
final 6 of the 28 aa in the transmembrane domain (DTM) for the
E2 sequences were conserved by both genotypes, an additional 13
aa were conserved in 1b sequences with no additional 1a
conserved positions.
Genotype 1a groups exhibited higher covariance values than
their 1b counterparts. The 50 highest covariance pairs were also
much more connected in 1a than 1b (Figure 3). These pairs for
each genotype overlap at position 216, and are close at 480(b),
481(a), 482(a) and 625(b), 626(a) and 653(b), 655(a) and 710(a),
712(b), 713(b). Positions that were directly connected in the
network for 1a showed similar subsequences for one subgroup. For
example, position 216 is directly connected to positions 243, 456,
655, 686 and 710 in the network in Figure 3. Twelve individuals
exhibited the sequence ATLESA at these positions with this exact
sequence for 10 of the 12 with 1 aa variation for the remaining two
individuals, compared to the sequence TTM(E/A)SA for 2
individuals, TAMFTV for 28 individuals, and TAMAT- for the
remaining individual. The 14 individuals with the ATLESA or
TTM(E/A)SA sequences form the bottom cluster in the phyloge-
netic tree for 1a. On the other hand the top cluster of 8 individuals
exhibits a gap at position 731 within DTM for E2, whereas all but
2 others do not. In summary, covarying networks, especially for
genotype 1a, can extract patients in different clusters and
determine those aa positions that typify those clusters. This
supports our hypothesis that networks of covarying pairs may also
provide a means to differentiate treatment response groups, and
that covarying networks can determine such features that may be
specific to an individual cluster.
Extracting optimal covarying networks that are
associated with response
Antiviral response groups cannot be separated on conserved
positions, nor will highly variable regions, by their very nature,
provide a robust means of predicting response. Hence we followed
the approach by Aurora et al. [21] who used covarying positions
HCV Features That Determine Antiviral Response
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over the entire HCV genome to form networks that were exhibited
by one response group but not the other. We hypothesized that
determining networks of covarying pairs that separated response
groups and satisfied certain optimality criteria might determine the
most relevant of these pairs, and hence provide the most robust
associations with response and point to the underlying process in
the HCV structure by which this occurs.
Optimal networks were determined based on whether a single
or multiple aa combinations were allowed at each separating pair,
whether the criteria was to minimize the number of pairs or to
maximize a measure of the total covariance, and whether we
extract features in the NR (Poor Response) or the SVR (Good
Response) groups. The covarying pairs can also be determined
over all individuals in a genotype, or from the SVR or NR patient
sequences. This led to 48 individual calculations and optimal
networks (Supporting Information Table S1).
Incorporating the covariance value into the optimization
criterion made little impact on the number of separating pairs in
the optimal network compared to the optimization criterion that
explicitly minimized the number of pairs, mostly due to both
criteria penalizing separating networks with high numbers of
edges. Combining the results for both of these criteria, the six
optimal networks for poor response allowing multiple aa
combinations at each pair only required 3 pairs in genotype 1a
(Table S1). Optimal genotype 1b networks required between 2
and 4 pairs. Only allowing single combinations understandably
increased the size of the optimal networks, ranging between 5 and
9 pairs.
E1 covered 192 out of the 555 aa positions (35%) yet these
appeared less frequently in optimal networks (Figure 4). For
multiple combinations: Poor Response (NR), 6 E1 positions
appeared among all 36 possible positions (twice the sum of the
total number of pairs in these 6 optimal networks, 17%) in 1a, and
3 of 30 (10%) in 1b; Good Response (SVR), 3% in 1a, and 8% for
1b. The frequency of E1 positions was higher when optimal
networks for single combinations were considered but was still
lower than the expected frequency of 35% under random choice:
Poor Response, 23% in 1a, and 14% in 1b; Good Response, 10%
in 1a, and 16% for 1b.
Allowing multiple aa combinations for each pair in the network
tended to result in pairs that contained a position within
hypervariable region 1 (HVR1, positions 384–410, 5% of E1E2,
Figure 4, [23–25]). For example each of the 3 pairs in the optimal
network for Good Response, 1a, where we minimized the number
of pairs and the separating set was SVR, contained a position
within HVR1 (396, 399, 407, Table S1). The pair 396–434 for
that network separated 6 SVR individuals but used 5 different aa
combinations (AH, AT, LK, TS, VD). The inherent variability of
positions within HVR1 resulted in many different separating pairs.
However this was not always the case: 399–524 separated 9 SVR
individuals based only on two aa combinations IA and LV, while
407–653 separated 4 SVR individuals with the single combination
PN. For multiple combinations: Poor Response, HVR1 appeared
in 36% of optimal networks for 1a, and 27% for 1b; Good
Response, 38% for 1a, and 38% for 1b. For single combination
networks: Poor Response, 14% for 1a, and 29% for 1b; Good
Response, 21% for 1a, and 27% of 1b. Hence HVR1 positions
were approximately 6 times more likely to occur in these optimal
networks than would be expected by chance.
Positions that coincided with hypervariable region 2 (HVR2,
positions 473–480, 1% of E1E2 [23]) that also cover part of the
first CD81 binding site, appeared only once in the 1a networks but
relatively frequently in the 1b networks (Table S1). For multiple
combinations in 1b: Poor Response, HVR2 positions appeared in
27% of 1b optimal networks; Good Response 23%. For single
combinations in 1b: Poor Response, 9%; Good Response 4%.
Hypervariable region 3 (HVR3) extends from positions 431 to
466 [26] and covers approximately 7% of the E1E2 genes. This
domain contained a relatively higher proportion of aa in the
optimal networks. For multiple combinations: Poor Response,
Figure 1. Phylogenetic tree of all individuals. Identifiers for nonresponders are coloured red. Reference strains H77 for 1a and J4
for 1b are also shown (blue).
doi:10.1371/journal.pone.0067254.g001
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Figure 2. Conserved and covarying regions for 1a and 1b genotypes. Regions are coloured as conserved across both genotypes (black),
conserved within each genotype (dark blue), conserved except for a maximum of 2 individuals in that genotype (light blue), and the positions within
50% of maximum covariance in each genotype (magenta) with the covarying pairs shown connected through magenta lines. Regions indicated: E1,
transmembrane domains (DTM), hypervariable regions (HVR1, HVR2, HVR3), CD81 binding sites (CD81), and PePHD.
doi:10.1371/journal.pone.0067254.g002
HCV Features That Determine Antiviral Response
PLOS ONE | www.plosone.org 6 June 2013 | Volume 8 | Issue 6 | e67254
19% for 1a, and 20% for 1b; Good Response, 18% for 1a, and
20% for 1b. For single combination networks: Poor Response, 7%
for 1a, and 12% for 1b; Good Response, 9% for 1a, and 9% of 1b.
Moreover 1b contained a greater number of different positions
within this domain (Figure 4), whereas 1a had fewer but with
position 434 being particularly prevalent and appearing 11 times
in 1a networks and 7 in 1b networks.
Positions in the CD81 binding sites (473–493 (1), 524–536 (2a),
544–555 (2b), 613–622 (3), [23–25]) appeared only once in the
optimal networks for CD81-2b and CD81-3, but were more
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Figure 3. Networks of highest covarying pairs. The 50 aa pairs with the highest covariance values calculated over all individuals in genotypes a
and b. Edges between nodes connect the covarying aa pairs.
doi:10.1371/journal.pone.0067254.g003
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Figure 4. Mapping of optimal covarying pairs. Collections of all separating pairs in the minimal networks for each problem where selection can
be within NR (Poor) or SVR (Good), for genotypes 1a and 1b, and where either only a single separating pair is chosen (Single), or multiple aa
combinations are allowed for each pair (Multiple). The E1E2 sequence that ranges from aa positions of 192 to 746 is shown separated into E1 (yellow)
with its transmembrane domain (DTM, darker yellow), HVR 1 and 3 (blue), with HVR2 that overlaps part of the CD81 binding site (green), the CD81
binding sites (CD81, orange and green where it overlaps with HVR2), PePHD (magenta), and the transmembrane domain for E2 (grey) [23,26].
doi:10.1371/journal.pone.0067254.g004
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frequent for domains 1 and 2a. In total for multiple combinations:
Poor Response, 3% for 1a, and 20% for 1b; Good Response, 21%
for 1a, and 25% for 1b. For single combination networks: Poor
Response, 9% for 1a, and 18% for 1b; Good Response, 19% for
1a, and 10% of 1b.
Although the protein kinase PKR /eukaryotic translation
initiation factor 2a phosphorylation homology domain (PePHD)
has been implicated in failure of interferon therapy in HCV [15],
none of the aa in this region (positions 659 to 670 [23]) appeared
in any of the optimal networks regardless of Good or Poor
response (Figure 4).
Some separating pairs appeared repeatedly within each set of
networks. The most frequent of these, appearing 5 times, was the
531–626 (EI) separating pair for single combinations, Poor
Response in 1a. This feature appeared in 6 of the nonresponders
within the lowest cluster of the phylogenetic tree for genotype 1a
(Figure 1). The most frequent pairs representing a Good Response
among single combination networks were 431–481 (EE), 500–522
(QA) in 1a, and 407–434 (AQ) in 1b, each appearing 4 times. The
most frequent of the individual positions appeared 7 times in their
group for single combinations: 387 (poor response, 1a), 395, 481,
522 (good response 1a), and 407 (good response 1b).
Discussion
Determining features in viral sequences that reflect likelihood of
failure of antiviral therapy is a difficult problem. Simply by chance
and the high variability of portions of these sequences, there will be
collections of aa at some positions that will only appear in one
response group. We instead based our analysis on aa pairs that
were correlated within genotypes as these are more likely to
indicate that evolutionary pressure has occurred at these positions
related to viral fitness. Rather than describing all such networks we
determined those that satisfied certain optimality criteria, reason-
ing that these were more likely to contain the most important
features that reflect treatment outcome. The optimal networks and
features we extract have 100% accuracy and 0% false discovery
rate describing antiviral response and achieve this with minimal
components. An alternative approach using Bayesian networks has
also been employed to extract HCV genome features predicting
response [27]. We found that therapy response groups could be
separated with as few as 2 aa pairs if we allowed multiple aa
combinations for these pairs, or with 5 pairs if only allowing a
single aa combination for each pair. Under these optimality
criteria there can be no fewer aa pairs that separate the groups.
This implies that there is no single feature that can be used in each
of these genotypes to predict therapy outcome, and probably
indicates the many evolutionary pathways that HCV can take
even within genotypes. This is particularly evident in genotype 1a
where the phylogenetic tree splits into 3 main clusters, whereas
genotype 1b sequences exhibit more random drift (Figure 1). It is
unlikely these 1a clusters can be attributed to transmission within
geographical sectors because the corresponding patients were
mainly caucasian without any evidence of epidemiological links
[16]. Thus the generation of the 3 genotype 1a clusters could be
due to classical evolutionary forces linked to host-related immunity
and viral fitness. However mode of transmission may play a part in
these linkages. Genotype 1a in France has been associated with
injecting drug users, while 1b is more prevalent among transfu-
sion-associated cases [28]. This association was also observed in
our HCV-infected cohort [16].
Further evidence of the different ways 1a and 1b viruses evolve
are provided by the collection of the 50 aa pairs with the highest
covariance (Figure 3). There were 9 separate subcomponents
containing 58 positions as nodes with maximum node degree of 4
in the 1b network whereas the 1a collection formed a highly
structured single component consisting of 18 nodes with maximum
node degree of 11. This structure did not seem to determine
therapy outcome however since SVR and NR individuals were
scattered within these subgroups (Figure 1). Nevertheless our
analysis did pick out some pairs that were present in responders
versus nonresponders within some of these groups. For instance
the 531–626 (EI) separating pair was indicative of a poor response
to this therapy for one of the 1a subgroups. Each of these positions
was highly prevalent in the optimal networks with position 531
(SVR:A, NR:E) occurring 13 different times and position 626
occurring 11 times (SVR:V, NR:I). These positions occurred
infrequently for 1b: 531 twice and 626 once. The 1a nonrespond-
ers who expressed the 531–626 (EI) pair or the 3 SVR individuals
with an A at position 531 are all grouped in the lower 1a cluster in
Figure 1. This group of 14 individuals is identified by the
ATLESA or TTM(E/A)SA sequences at positions 216, 243,
456, 655, 686 and 710 in the network in Figure 3A. It is of interest
that the calculations of minimal networks has extracted aa features
for this subgroup that determines within this group what is
indicative of therapy failure or success. So although a single feature
cannot predict treatment outcome, within this phylogenetic cluster
a single feature does exist. Position 531 is situated in the 2a CD81
binding site and is adjacent to the glycosylation site at position 532.
Similarly position 626 is next to the glycosylation site that is coded
by 623–625. A subtle change in aa composition of HCV envelope
glycoproteins has been demonstrated to modify their immunity
and/or viral entry efficiency [12,16,29]. It can be hypothesized
that the presence of a negatively charged E at 531 versus the
hydrophobic A could influence HCV immunity or the entry step
into hepatocytes.
HVR2 was much more likely to appear in 1b networks than
would occur by chance, whereas it appeared only once in the 1a
networks. The other hypervariable regions were also highly
prevalent in the networks but this did not differ between
genotypes. Except for a single occurrence, only the CD81 binding
regions 1 and 2a appeared in the networks, where region 2a
overlaps with HVR2. Although the PePHD domain has been
implicated in the failure of interferon therapy none of these
positions appeared in these networks.
There are several limitations to our methods. One of these is
that the calculation of the optimal separating set determines one
such optimal set for each problem where there may be a number
of optimal solutions. Hence our method does not necessarily
extract all the pairs that may influence response to therapy and so
these are only subnetworks of the important positions and pairs.
Furthermore only the dominant sequence in an individual’s viral
quasispecies was determined. Viral clones that are present at low
frequency before the commencement of therapy may play a major
role in its failure, and our analysis did not incorporate this aspect.
Deep sequencing may uncover greater information on which to
base predictions of treatment response, but would certainly
complicate the analysis.
In summary, this approach of determining optimal sets of
covarying pairs has identified regions of particular importance to
differentiating an individual’s response to antiviral therapy for
HCV. It has also quantified the difficulty in achieving response
and the different pathways the virus can take to evade clearance
given that there were no single pairs that completely separated
response groups. No fewer than 5 aa pairs were required to
separate response groups when allowing single combinations for
each pair. The optimal covarying networks determined here have
extracted regions for further in vitro investigation.
HCV Features That Determine Antiviral Response
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